We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
- Authors
Knorr, B; Franchi, L M; Bisgaard, H; Vermeulen, J H; LeSouef, P; Santanello, N; Michele, T M; Reiss, T F; Nguyen, H H; Bratton, D L
- Abstract
The greatest prevalence of asthma is in preschool children; however, the clinical utility of asthma therapy for this age group is limited by a narrow therapeutic index, long-term tolerability, and frequency and/or difficulty of administration. Inhaled corticosteroids and inhaled cromolyn are the most commonly prescribed controller therapies for young children with persistent asthma, although very young patients may have difficulty using inhalers, and dose delivery can be variable. Moreover, reduced compliance with inhaled therapy relative to orally administered therapy has been reported. One potential advantage of montelukast is the ease of administering a once-daily chewable tablet; additionally, no tachyphylaxis or change in the safety profile has been evidenced after up to 140 and 80 weeks of montelukast therapy in adults and pediatric patients aged 6 to 14 years, respectively. To our knowledge, this represents the first large, multicenter study to address the effects of a leukotriene receptor antagonist in children younger than 5 years of age with persistent asthma, as well as one of the few asthma studies that incorporated end points validated for use in preschool children.
- Publication
Pediatrics, 2001, Vol 108, Issue 3, pE48
- ISSN
1098-4275
- Publication type
Journal Article
- DOI
10.1542/peds.108.3.e48